Skip to main content
SpringerLink
Log in
Book cover

Handbook of Evidence-Based Stereotactic Radiosurgery and Stereotactic Body Radiotherapy pp 165–181Cite as

Genitourinary Sites

  • Chapter

  • 1486 Accesses

Abstract

Stereotactic body radiotherapy (SBRT) for prostate cancer is rapidly growing in popularity, with multiple large phase II clinical trials showing excellent tumor control and acceptable toxicity. The use of SBRT has also been studied, although less extensively, for other genitourinary sites, including bladder cancer and renal cell carcinoma. We review the literature supporting SBRT for each of these sites and discuss practical aspects of SBRT planning and delivery, including simulation and field design, dose prescriptions and dose constraints, and expected toxicity and management.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Aluwini S, van Rooij P, Hoogeman M, Kirkels W, Kolkman-Deurloo I-K, et al. Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results. Radiat Oncol. 2013;8:84. doi:10.1186/1748-717X-8-84.

    Article  PubMed Central  PubMed  Google Scholar 

  • Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010;37:4078–101.

    Article  PubMed  Google Scholar 

  • Boike TPT, Lotan YY, Cho LCL, Brindle JJ, DeRose PP, et al. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol. 2011;29:2020–6. doi:10.1200/JCO.2010.31.4377.

    Article  PubMed Central  PubMed  Google Scholar 

  • Bolzicco G, Favretto MS, Satariano N, Scremin E, Tambone C, et al. A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy. BMC Urol. 2013;13:49. doi:10.1186/1471-2490-13-49.

    Article  PubMed Central  PubMed  Google Scholar 

  • Chen LN, Suy S, Uhm S, Oermann EK, Ju AW, et al. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol. 2013;8:58. doi:10.1186/1748-717X-8-58.

    Article  PubMed Central  PubMed  Google Scholar 

  • Fuller DB, Naitoh J, Lee C, Hardy S, Jin H (2008) Virtual HDRSM CyberKnife Treatment for Localized Prostatic Carcinoma: Dosimetry Comparison With HDR Brachytherapy and Preliminary Clinical Observations. International Journal of Radiation Oncology*Biology*Physics 70: 1588–1597. doi:10.1016/j.ijrobp.2007.11.067.

    Google Scholar 

  • Hinnen KAK, Monninkhof EME, Battermann JJJ, van Roermund JGHJ, Frank SJS, et al. Prostate specific antigen bounce is related to overall survival in prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2012;82:883–8. doi:10.1016/j.ijrobp.2010.11.049.

    Article  PubMed  Google Scholar 

  • Jabbari SS, Weinberg VKV, Kaprealian TT, Hsu I-CI, Ma LL, et al. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Int J Radiat Oncol Biol Phys. 2012;82:228–34. doi:10.1016/j.ijrobp.2010.10.026.

    Article  PubMed  Google Scholar 

  • Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol. 2010a;10:1–1. doi:10.1186/1471-2490-10-1.

    Article  PubMed Central  PubMed  Google Scholar 

  • Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M. Stereotactic body radiotherapy as boost for organ-confined prostate cancer. Technol Cancer Res Treat. 2010b;9:575–82.

    Article  PubMed  Google Scholar 

  • Katz AJ, Santoro M, Diblasio F, Ashley R. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol. 2013;8:118. doi:10.1186/1748-717X-8-118.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, et al. Stereotactic Body Radiotherapy for Localized Prostate Cancer: Interim Results of a Prospective Phase II Clinical Trial. Int J Radiat Oncol Biol Phys. 2009;73:6–6. doi:10.1016/j.ijrobp.2008.05.059.

    Article  Google Scholar 

  • King CR, Brooks JD, Gill H, Presti JC Jr. (2012) Long-Term Outcomes From a Prospective Trial of Stereotactic Body Radiotherapy for Low-Risk Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics 82: 877–882. doi:10.1016/j.ijrobp.2010.11.054.

    Google Scholar 

  • King CR, Collins S, Fuller D, Wang P-C, Kupelian P, et al. Health-Related Quality of Life After Stereotactic Body Radiation Therapy for Localized Prostate. Cancer: Results From a Multi-institutional Consortium of Prospective Trials. Int J Radiat Oncol Biol Phys; 2013a. doi:10.1016/j.ijrobp.2013.08.019.

    Google Scholar 

  • King CR, Freeman D, Kaplan I, Fuller D, Bolzicco G, et al. Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol. 2013b. doi:10.1016/j.radonc.2013.08.030.

    PubMed  Google Scholar 

  • Loblaw A, Cheung P, D'Alimonte L, Deabreu A, Mamedov A, et al. Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes. Radiother Oncol. 2013;107:153–8. doi:10.1016/j.radonc.2013.03.022.

    Article  PubMed  Google Scholar 

  • Madsen BLB, Hsi RAR, Pham HTH, Fowler JFJ, Esagui LL, et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results. Int J Radiat Oncol Biol Phys. 2007;67:7–7. doi:10.1016/j.ijrobp.2006.10.050.

    Article  Google Scholar 

  • McBride SMS, Wong DSD, Dombrowski JJJ, Harkins BB, Tapella PP, et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer. 2012;118:3681–90. doi:10.1002/cncr.26699.

    Article  PubMed  Google Scholar 

  • Miralbell R, Moll M, Rouzaud M, Hidalgo A, Toscas JI, et al. Hypofractionated Boost to the Dominant Tumor Region With Intensity Modulated Stereotactic Radiotherapy for Prostate Cancer: A Sequential Dose Escalation Pilot Study. Int J Radiat Oncol Biol Phys. 2010;78:50–7. doi:10.1016/j.ijrobp.2009.07.1689.

    Article  PubMed  Google Scholar 

  • Miralbell RR, Roberts SAS, Zubizarreta EE, Hendry JHJ. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys. 2012;82:e17–24. doi:10.1016/j.ijrobp.2010.10.075.

    Article  PubMed  Google Scholar 

  • National Comprehensive Cancer Network. Prostate Cancer (Version 1.2014). http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed October 28, 2014.

  • Ning S, Trisler K, Wessels BW, Knox SJ. Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer. 1997;80:2519–28.

    Article  CAS  PubMed  Google Scholar 

  • Parthan A, Pruttivarasin N, Davies D, Taylor DCA, Pawar V, et al. Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer. Front Oncol. 2012;2:81. doi:10.3389/fonc.2012.00081.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Sher DJ, Parikh R, Mays-Jackson S, Punglia RS (2012) Cost-effectiveness Analysis of SBRT Versus IMRT for Low-risk Prostate Cancer. American Journal of Clinical Oncology: –. doi:10.1097/COC.0b013e31827a7d2a.

    Google Scholar 

  • Simone NL, Ménard C, Soule BP, Albert PS, Guion P, et al. Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score. Int J Radiat Oncol Biol Phys. 2008;70:90–5. doi:10.1016/j.ijrobp.2007.05.057.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Svedman CC, Karlsson KK, Rutkowska EE, Sandström PP, Blomgren HH, et al. Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney. Acta Oncol. 2008;47:1578–83. doi:10.1080/02841860802123196.

    Article  CAS  PubMed  Google Scholar 

  • Syljuåsen RGR, Belldegrun AA, Tso CLC, Withers HRH, McBride WHW. Sensitization of renal carcinoma to radiation using alpha interferon (IFNA) gene transfection. Radiat Res. 1997;148:443–8.

    Article  PubMed  Google Scholar 

  • Thariat JJ, Trimaud RR, Angellier GG, Caullery MM, Amiel JJ, et al. Innovative image-guided CyberKnife stereotactic radiotherapy for bladder cancer. Br J Radiol. 2010;83:e118–21. doi:10.1259/bjr/26397829.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Wei K, Wandl E, Kärcher KH. X-ray induced DNA double-strand breakage and rejoining in a radiosensitive human renal carcinoma cell line estimated by CHEF electrophoresis. Strahlenther Onkol. 1993;169:740–4.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, University of California San Francisco, 1600 Divisadero Street, Suite H1031, San Francisco, CA, USA

    Michael Wahl MD, Albert J. Chang MD, PhD & Alexander R. Gottschalk MD, PhD

  2. Department of Radiation Oncology and Urology, University of California San Francisco, 1600 Divisadero Street, Suite H1031, San Francisco, CA, USA

    Mack Roach III MD

Authors
  1. Michael Wahl MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Albert J. Chang MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alexander R. Gottschalk MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mack Roach III MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, University of California, San Francisco, San Francisco, California, USA

    Rajni A. Sethi

  2. Departments of Radiation Oncology & Neurological Surgery, University of California, San Francisco, San Francisco, California, USA

    Igor J. Barani

  3. Department of Radiation Oncology and Urology, University of California, San Francisco, San Francisco, California, USA

    David A. Larson

  4. Department of Radiation Oncology and Urology, University of California, San Francisco, San Francisco, California, USA

    Mack Roach, III

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Wahl, M., Chang, A.J., Gottschalk, A.R., Roach, M. (2016). Genitourinary Sites. In: Sethi, R., Barani, I., Larson, D., Roach, III, M. (eds) Handbook of Evidence-Based Stereotactic Radiosurgery and Stereotactic Body Radiotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-21897-7_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-21897-7_9

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-21896-0

  • Online ISBN: 978-3-319-21897-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation